Literature DB >> 9367943

Oligosymptomatic neurosyphilis with false negative CSF-VDRL in HIV-infected individuals?

R Malessa1, M W Agelink, U Hengge, L Mertins, M Gastpar, N H Brockmeyer.   

Abstract

The true prevalence of neurosyphilis in HIV-infection is unknown, since a sufficiently sensitive and specific test is lacking. In a prospective study we found reactive serum TPHA and FTA-ABS IgG tests in 95 (31%) of 307 HIV-infected patients. Three of 11 patients with latent syphilis revealed reactive CSF-VDRL tests, six others only demonstrated CSF abnormalities. Resolution of CSF abnormalities during a six month follow up after high dose antibiotic therapy led to the diagnosis of oligosymptomatic or asymptomatic neurosyphilis in all nine patients. Thus, the specificity of the CSF-VDRL was 100%, but the sensitivity was only 33%. The overall prevalence of neurosyphilis was 2.9%, increasing to 9.5% in patients with a reactive serum TPHA. Our study emphasizes the importance of antibiotic therapy for presumptive neurosyphilis in HIV-infected patients with latent syphilis and CSF abnormalities but nonreactive CSF-VDRL tests, even if they are neurologically asymptomatic or present with complaints inconclusive of neurosyphilis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9367943

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  3 in total

1.  [Syphilis and HIV infection. Characteristic features of diagnosis, clinical assessment, and treatment].

Authors:  A Potthoff; N H Brockmeyer
Journal:  Hautarzt       Date:  2005-02       Impact factor: 0.751

Review 2.  [Diagnosis and therapy of genitoanal ulcers of infectious etiology].

Authors:  B Malisiewicz; H Schöfer
Journal:  Hautarzt       Date:  2015-01       Impact factor: 0.751

3.  [Neurosyphilis and concomitant secondary syphilis in an HIV-infected patient].

Authors:  A Marini; B Prange; A Kuhn; M Megahed; T Ruzicka; U R Hengge
Journal:  Hautarzt       Date:  2004-10       Impact factor: 0.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.